VERACYTE INC (VCYT) Fundamental Analysis & Valuation

NASDAQ:VCYT • US92337F1075

Current stock price

32.13 USD
+1.2 (+3.88%)
At close:
32.56 USD
+0.43 (+1.34%)
After Hours:

This VCYT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. VCYT Profitability Analysis

1.1 Basic Checks

  • In the past year VCYT was profitable.
  • VCYT had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: VCYT reported negative net income in multiple years.
  • VCYT had a positive operating cash flow in 4 of the past 5 years.
VCYT Yearly Net Income VS EBIT VS OCF VS FCFVCYT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M

1.2 Ratios

  • VCYT's Return On Assets of 4.72% is amongst the best of the industry. VCYT outperforms 91.14% of its industry peers.
  • VCYT has a Return On Equity of 5.07%. This is amongst the best in the industry. VCYT outperforms 90.56% of its industry peers.
  • VCYT has a better Return On Invested Capital (4.59%) than 90.94% of its industry peers.
Industry RankSector Rank
ROA 4.72%
ROE 5.07%
ROIC 4.59%
ROA(3y)-0.03%
ROA(5y)-1.93%
ROE(3y)0%
ROE(5y)-2.06%
ROIC(3y)N/A
ROIC(5y)N/A
VCYT Yearly ROA, ROE, ROICVCYT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • VCYT's Profit Margin of 12.83% is amongst the best of the industry. VCYT outperforms 91.91% of its industry peers.
  • VCYT has a better Operating Margin (15.14%) than 92.29% of its industry peers.
  • Looking at the Gross Margin, with a value of 70.10%, VCYT belongs to the top of the industry, outperforming 80.92% of the companies in the same industry.
  • VCYT's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 15.14%
PM (TTM) 12.83%
GM 70.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.15%
GM growth 5Y1.62%
VCYT Yearly Profit, Operating, Gross MarginsVCYT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

8

2. VCYT Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), VCYT is destroying value.
  • VCYT has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, VCYT has more shares outstanding
  • There is no outstanding debt for VCYT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VCYT Yearly Shares OutstandingVCYT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
VCYT Yearly Total Debt VS Total AssetsVCYT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

2.2 Solvency

  • VCYT has an Altman-Z score of 15.83. This indicates that VCYT is financially healthy and has little risk of bankruptcy at the moment.
  • VCYT has a better Altman-Z score (15.83) than 86.51% of its industry peers.
  • VCYT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 15.83
ROIC/WACC0.52
WACC8.91%
VCYT Yearly LT Debt VS Equity VS FCFVCYT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 8.15 indicates that VCYT has no problem at all paying its short term obligations.
  • VCYT has a better Current ratio (8.15) than 73.60% of its industry peers.
  • VCYT has a Quick Ratio of 7.81. This indicates that VCYT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 7.81, VCYT is in the better half of the industry, outperforming 72.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.15
Quick Ratio 7.81
VCYT Yearly Current Assets VS Current LiabilitesVCYT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

7

3. VCYT Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 176.67% over the past year.
  • The Revenue has grown by 16.01% in the past year. This is quite good.
  • VCYT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 34.50% yearly.
EPS 1Y (TTM)176.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%750%
Revenue 1Y (TTM)16.01%
Revenue growth 3Y20.37%
Revenue growth 5Y34.5%
Sales Q2Q%18.55%

3.2 Future

  • Based on estimates for the next years, VCYT will show a very strong growth in Earnings Per Share. The EPS will grow by 21.22% on average per year.
  • VCYT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.74% yearly.
EPS Next Y39.38%
EPS Next 2Y26.95%
EPS Next 3Y26.37%
EPS Next 5Y21.22%
Revenue Next Year12.64%
Revenue Next 2Y12.58%
Revenue Next 3Y12.06%
Revenue Next 5Y10.74%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
VCYT Yearly Revenue VS EstimatesVCYT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
VCYT Yearly EPS VS EstimatesVCYT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 2

6

4. VCYT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 38.71, which means the current valuation is very expensive for VCYT.
  • Based on the Price/Earnings ratio, VCYT is valued cheaply inside the industry as 90.75% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 25.70, VCYT is valued quite expensively.
  • The Price/Forward Earnings ratio is 27.77, which means the current valuation is very expensive for VCYT.
  • 92.87% of the companies in the same industry are more expensive than VCYT, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of VCYT to the average of the S&P500 Index (23.84), we can say VCYT is valued inline with the index average.
Industry RankSector Rank
PE 38.71
Fwd PE 27.77
VCYT Price Earnings VS Forward Price EarningsVCYT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VCYT indicates a rather cheap valuation: VCYT is cheaper than 93.26% of the companies listed in the same industry.
  • VCYT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VCYT is cheaper than 95.95% of the companies in the same industry.
Industry RankSector Rank
P/FCF 20.16
EV/EBITDA 20.01
VCYT Per share dataVCYT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • VCYT has a very decent profitability rating, which may justify a higher PE ratio.
  • VCYT's earnings are expected to grow with 26.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.98
PEG (5Y)N/A
EPS Next 2Y26.95%
EPS Next 3Y26.37%

0

5. VCYT Dividend Analysis

5.1 Amount

  • No dividends for VCYT!.
Industry RankSector Rank
Dividend Yield 0%

VCYT Fundamentals: All Metrics, Ratios and Statistics

VERACYTE INC

NASDAQ:VCYT (3/13/2026, 8:02:09 PM)

After market: 32.56 +0.43 (+1.34%)

32.13

+1.2 (+3.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners110.45%
Inst Owner Change-4.94%
Ins Owners0.42%
Ins Owner Change6.05%
Market Cap2.55B
Revenue(TTM)517.14M
Net Income(TTM)66.35M
Analysts82.11
Price Target50.17 (56.15%)
Short Float %7.67%
Short Ratio7.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)105.79%
Min EPS beat(2)79.03%
Max EPS beat(2)132.56%
EPS beat(4)3
Avg EPS beat(4)43.36%
Min EPS beat(4)-110.32%
Max EPS beat(4)132.56%
EPS beat(8)6
Avg EPS beat(8)164.25%
EPS beat(12)8
Avg EPS beat(12)72.71%
EPS beat(16)12
Avg EPS beat(16)65.75%
Revenue beat(2)2
Avg Revenue beat(2)3.25%
Min Revenue beat(2)3.19%
Max Revenue beat(2)3.31%
Revenue beat(4)4
Avg Revenue beat(4)3.32%
Min Revenue beat(4)1.01%
Max Revenue beat(4)5.76%
Revenue beat(8)7
Avg Revenue beat(8)3.84%
Revenue beat(12)11
Avg Revenue beat(12)4.44%
Revenue beat(16)15
Avg Revenue beat(16)5.09%
PT rev (1m)0.93%
PT rev (3m)1.69%
EPS NQ rev (1m)5.09%
EPS NQ rev (3m)-9.81%
EPS NY rev (1m)2.37%
EPS NY rev (3m)10.57%
Revenue NQ rev (1m)0.6%
Revenue NQ rev (3m)0.44%
Revenue NY rev (1m)1.2%
Revenue NY rev (3m)2.33%
Valuation
Industry RankSector Rank
PE 38.71
Fwd PE 27.77
P/S 4.94
P/FCF 20.16
P/OCF 18.73
P/B 1.95
P/tB 5.63
EV/EBITDA 20.01
EPS(TTM)0.83
EY2.58%
EPS(NY)1.16
Fwd EY3.6%
FCF(TTM)1.59
FCFY4.96%
OCF(TTM)1.72
OCFY5.34%
SpS6.51
BVpS16.48
TBVpS5.7
PEG (NY)0.98
PEG (5Y)N/A
Graham Number17.54
Profitability
Industry RankSector Rank
ROA 4.72%
ROE 5.07%
ROCE 5.82%
ROIC 4.59%
ROICexc 6.63%
ROICexgc 80.43%
OM 15.14%
PM (TTM) 12.83%
GM 70.1%
FCFM 24.49%
ROA(3y)-0.03%
ROA(5y)-1.93%
ROE(3y)0%
ROE(5y)-2.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.15%
GM growth 5Y1.62%
F-Score8
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 45.19%
Cap/Sales 1.87%
Interest Coverage 250
Cash Conversion 136.72%
Profit Quality 190.84%
Current Ratio 8.15
Quick Ratio 7.81
Altman-Z 15.83
F-Score8
WACC8.91%
ROIC/WACC0.52
Cap/Depr(3y)43.31%
Cap/Depr(5y)38.08%
Cap/Sales(3y)2.39%
Cap/Sales(5y)2.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)176.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%750%
EPS Next Y39.38%
EPS Next 2Y26.95%
EPS Next 3Y26.37%
EPS Next 5Y21.22%
Revenue 1Y (TTM)16.01%
Revenue growth 3Y20.37%
Revenue growth 5Y34.5%
Sales Q2Q%18.55%
Revenue Next Year12.64%
Revenue Next 2Y12.58%
Revenue Next 3Y12.06%
Revenue Next 5Y10.74%
EBIT growth 1Y301.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year205.84%
EBIT Next 3Y58.94%
EBIT Next 5Y37.52%
FCF growth 1Y98.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y81.51%
OCF growth 3Y162.45%
OCF growth 5YN/A

VERACYTE INC / VCYT Fundamental Analysis FAQ

What is the fundamental rating for VCYT stock?

ChartMill assigns a fundamental rating of 7 / 10 to VCYT.


What is the valuation status of VERACYTE INC (VCYT) stock?

ChartMill assigns a valuation rating of 6 / 10 to VERACYTE INC (VCYT). This can be considered as Fairly Valued.


How profitable is VERACYTE INC (VCYT) stock?

VERACYTE INC (VCYT) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for VCYT stock?

The Price/Earnings (PE) ratio for VERACYTE INC (VCYT) is 38.71 and the Price/Book (PB) ratio is 1.95.


What is the financial health of VERACYTE INC (VCYT) stock?

The financial health rating of VERACYTE INC (VCYT) is 8 / 10.